Canada
BC Cancer
ovarian neoplasms, antigen, CA-125, kinetics, chemosensitivity, prognostic biomarker, surrogacy
ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor
checkpoint inhibitors, rare cancers, ovarian carcinoma